Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sarepta Therapeutics

18.24
+0.04500.25%
Post-market: 18.21-0.0299-0.16%16:58 EDT
Volume:2.48M
Turnover:45.32M
Market Cap:1.79B
PE:-7.04
High:18.64
Open:18.45
Low:18.02
Close:18.20
Loading ...

Mizuho cuts Sarepta target, sees buying opportunity after selloff

TIPRANKS
·
18 Jun

TD Cowen Downgrades Sarepta Therapeutics to Hold From Buy, Cuts Price Target to $24 From $62

MT Newswires Live
·
18 Jun

U.S. RESEARCH ROUNDUP-American Airlines, Jabil, Lennar

Reuters
·
18 Jun

Sarepta Therapeutics Inc : TD Cowen Cuts to Hold From Buy; Cuts Target Price to $24 From $62

THOMSON REUTERS
·
18 Jun

Evercore ISI Remains a Hold on Sarepta Therapeutics (SRPT)

TIPRANKS
·
18 Jun

Sarepta Therapeutics: Overcoming Challenges and Capturing Growth Opportunities Amid Elevidys Setback

TIPRANKS
·
18 Jun

Sarepta Therapeutics Inc : Morgan Stanley Cuts to Equal-Weight From Overweight

THOMSON REUTERS
·
17 Jun

Sarepta Therapeutics Is Maintained at Overweight by Barclays

Dow Jones
·
17 Jun

Sarepta Therapeutics Inc : Morgan Stanley Cuts to Equal-Weight

THOMSON REUTERS
·
17 Jun

Sarepta Therapeutics Inc : Bofa Global Research Cuts to Neutral From Buy; Cuts Price Objective to $28 From $76

THOMSON REUTERS
·
17 Jun

Sarepta Therapeutics Inc : Morgan Stanley Cuts to Equal-Weight From Overweight

THOMSON REUTERS
·
17 Jun

Sarepta Therapeutics Inc : Wells Fargo Cuts Target Price to $75 From $100

THOMSON REUTERS
·
17 Jun

U.S. RESEARCH ROUNDUP-Alphabet, Booking Holdings, Meta

Reuters
·
17 Jun

Sarepta Therapeutics Inc : TD Cowen Cuts Target Price to $62 From $137

THOMSON REUTERS
·
17 Jun

Sarepta Therapeutics Inc : Jefferies Cuts Target Price to $54 From $125

THOMSON REUTERS
·
17 Jun

Sarepta Therapeutics Inc : Leerink Partners Cuts Target Price to $50 From $100

THOMSON REUTERS
·
17 Jun

Stock Track | Sarepta Therapeutics Soars 5.01% After Hours on Hopes for Enhanced Safety Protocol

Stock Track
·
17 Jun

Stock Track | Sarepta Therapeutics Soars 5.01% After Hours on Potential FDA Review of Enhanced Safety Protocol

Stock Track
·
17 Jun

US HHS Says FDA Aware Of Second Reported Fatal Case Of Severe Liver Failure Due To Sarepta Gene Therapy

Reuters
·
17 Jun

US Hhs-FDA Aware of Second Reported Fatal Case of Severe Liver Failure Due to Sarepta Gene Therapy, Treating Situation With Highest Level of Concern

THOMSON REUTERS
·
17 Jun